PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-22.30%
Negative net income growth while TRAW stands at 18.00%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
24.17%
Some D&A expansion while TRAW is negative at -15.79%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
100.00%
Deferred tax of 100.00% while TRAW is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
-9.33%
Both cut yoy SBC, with TRAW at -26.26%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
-80.33%
Both reduce yoy usage, with TRAW at -90.57%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-46.04%
Negative yoy AP while TRAW is 13.07%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
-249.09%
Both reduce yoy usage, with TRAW at -209.60%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
-101.42%
Both negative yoy, with TRAW at -1022.73%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
-72.30%
Both yoy CFO lines are negative, with TRAW at -17.89%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
-455.28%
Negative yoy CapEx while TRAW is 0.00%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Growth of 100.00% while TRAW is zero at 0.00%. Bruce Berkowitz sees a moderate difference requiring justification by ROI in these smaller invests.
-427.62%
We reduce yoy invests while TRAW stands at 0.00%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
No Data
No Data available this quarter, please select a different quarter.
53916.27%
Stock issuance far above TRAW's 736.53%. Michael Burry flags a significant dilution risk vs. competitor’s approach unless ROI is very high.
No Data
No Data available this quarter, please select a different quarter.